Brief Communication
Treatment Persistence and Safety of Apremilast in Psoriasis: Experience With 30 Patients in Routine Clinical Practice
Persistencia y seguridad del apremilast en el tratamiento de la psoriasis en la práctica clínica habitual: experiencia en 30 pacientes
Leído
5180
Vecesse ha leído el artículo
1793
Total PDF
3387
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 32 | 4 | 36 |
| 2025 5 | 160 | 31 | 191 |
| 2025 4 | 143 | 17 | 160 |
| 2025 3 | 114 | 19 | 133 |
| 2025 2 | 147 | 25 | 172 |
| 2025 1 | 85 | 23 | 108 |
| 2024 12 | 69 | 35 | 104 |
| 2024 11 | 105 | 42 | 147 |
| 2024 10 | 72 | 46 | 118 |
| 2024 9 | 85 | 25 | 110 |
| 2024 8 | 99 | 65 | 164 |
| 2024 7 | 81 | 38 | 119 |
| 2024 6 | 76 | 27 | 103 |
| 2024 5 | 82 | 26 | 108 |
| 2024 4 | 81 | 21 | 102 |
| 2024 3 | 56 | 27 | 83 |
| 2024 2 | 54 | 29 | 83 |
| 2024 1 | 59 | 35 | 94 |
| 2023 12 | 49 | 14 | 63 |
| 2023 11 | 66 | 26 | 92 |
| 2023 10 | 47 | 25 | 72 |
| 2023 9 | 48 | 30 | 78 |
| 2023 8 | 42 | 13 | 55 |
| 2023 7 | 51 | 25 | 76 |
| 2023 6 | 39 | 20 | 59 |
| 2023 5 | 45 | 21 | 66 |
| 2023 4 | 32 | 16 | 48 |
| 2023 3 | 50 | 27 | 77 |
| 2023 2 | 34 | 26 | 60 |
| 2022 1 | 45 | 28 | 73 |
| 2022 12 | 59 | 37 | 96 |
| 2022 11 | 28 | 27 | 55 |
| 2022 10 | 29 | 24 | 53 |
| 2022 9 | 30 | 43 | 73 |
| 2022 8 | 34 | 41 | 75 |
| 2022 7 | 19 | 31 | 50 |
| 2022 6 | 27 | 31 | 58 |
| 2022 5 | 46 | 33 | 79 |
| 2022 4 | 36 | 36 | 72 |
| 2022 3 | 47 | 58 | 105 |
| 2022 2 | 38 | 33 | 71 |
| 2021 1 | 33 | 40 | 73 |
| 2021 12 | 34 | 39 | 73 |
| 2021 11 | 45 | 42 | 87 |
| 2021 10 | 94 | 50 | 144 |
| 2021 9 | 53 | 30 | 83 |
| 2021 8 | 49 | 22 | 71 |
| 2021 7 | 15 | 18 | 33 |
| 2021 6 | 22 | 24 | 46 |
| 2021 5 | 32 | 50 | 82 |
| 2021 4 | 62 | 42 | 104 |
| 2021 3 | 32 | 37 | 69 |
| 2021 2 | 38 | 30 | 68 |
| 2020 1 | 41 | 14 | 55 |
| 2020 12 | 29 | 18 | 47 |
| 2020 11 | 27 | 16 | 43 |
| 2020 10 | 23 | 16 | 39 |
| 2020 9 | 38 | 24 | 62 |
| 2020 8 | 70 | 34 | 104 |
| 2020 7 | 91 | 29 | 120 |
| 2020 6 | 18 | 18 | 36 |
Mostrar todo
